Clinical trials: Respiratory Viral Infections
Influenza, Human
Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults
This is a safety and Immunogenicity first-in-human dose-ranging study of self-amplifying RNA Seasonal Influenza Vaccine (ARCT-2138) in adults.
- Trial name
- NCT06125691
- Testing
- ARCT-2138, Licensed Quadrivalent Vaccine for younger adults, Licensed Quadrivalent Vaccine for older adults
- Where
- 2 sites in Australia
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
Influenza
Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 Years
The study will evaluate the immune response and the tolerability of the influenza vaccine administered in children aged 6-13 years old.
- Trial name
- NCT00372255
- Testing
- Influsplit SSW® 2005/2006
- Where
- 18 sites in Germany
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine
The aim of this study is to evaluate the safety and immunogenicity of Fluzone® Quadrivalent vaccine in participants aged 6 months to < 9 years at enrollment, divided into 2 age strata (6 months to < 36 months and 3 years to < 9…
- Trial name
- NCT01946425
- Testing
- Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza (Pandemic)
A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant
This is a randomized, observer-blinded, placebo-controlled trial in adults 18 to 64 years old. Randomization will be stratified by age (18 to 49 years and 50 to 64 years) and by prior influenza immunization within the past three…
- Trial name
- NCT02078674
- Testing
- Monovalent Avian Influenza VLP (H7N9), Matrix-M1™ adjuvant
- Where
- 5 sites in United States
- Volunteers
- 610 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza Immunization, Healthy Volunteers
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
This was a phase IV, multi-center, open-label study. The study collected serum samples from children 6 months to less than (<) 9 years of age who received Fluzone Quadrivalent vaccine and adults greater than or equal to (>=) 65…
- Trial name
- NCT05050318
- Testing
- Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Respiratory Syncytial Virus Infections
Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset
This study will use a retrospective cohort design and will be conducted within routinely collected national healthcare and statutory demographic datasets held by PHS and National Records of Scotland (NRS).
- Trial name
- BORLAND (NCT07235397)
- Testing
- ABRYSVO
- Volunteers
- 1 people
- Sponsor
- Pfizer
Respiratory Syncytial Virus Infection
A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection
The purpose of this study is to learn about the safety and effects of sisunatovir. Sisunatovir is studied for the possible treatment of Respiratory Syncytial Virus (RSV).
- Trial name
- NCT06079320
- Testing
- Sisunatovir
- Where
- 19 sites in United States, China and 2 more
- Volunteers
- 16 people
- Sponsor
- Pfizer
COVID-19, Coronavirus Infection
Relative Bioavailability Study of CX2101A for the Treatment of COVID-19
The study comprises three parts: single ascending dose (SAD) studies of CX2101A tablets at 40 mg, 100 mg, and 160 mg; a relative bioavailability (BA) study comparing single-dose administration of 100 mg CX2101A tablets and…
- Trial name
- NCT06864182
- Testing
- CX2101A tablet, CX2101A enteric-coated tablet
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Heronova Pharmaceuticals
SARS CoV 2 Infection, Influenza, Human
A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19
This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults…
- Trial name
- NCT05981846
- Testing
- BIMERVAX, SIIV
- Where
- 8 sites in Spain
- Volunteers
- 279 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
Influenza
Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults
The purpose of this study is to evaluate the safety and immune response of two-doses of GSK Biologicals' candidate influenza vaccine GSK 1557484A with or without adjuvant in adults.
- Trial name
- NCT00510874
- Testing
- Pumarix™, Pandemrix ™
- Where
- 10 sites in United States, Canada
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diphtheria, Tetanus
Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine
The purpose of this study is to evaluate the long term immunogenicity produced in children by the investigational hexavalent vaccine (DTaP-IPV-Hep B-PRP-T) given in Study A3L15 (NCT 00362336).
- Conditions
- Diphtheria, Tetanus, Whooping Cough, Hepatitis B
- Trial name
- NCT01105559
- Where
- 2 sites in South Africa
- Volunteers
- 455 people, healthy volunteers welcome
- Sponsor
- Sanofi
COVID-19
Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients
The proposed project will pilot incorporation of rapid serial measurements of IP-10 into a CDS tool for moderate and severe COVID-19 patients.
- Trial name
- NCT04389645
- Testing
- IP-10 in CDS protocol
- Where
- Israel
- Volunteers
- 52 people
- Sponsor
- MeMed Diagnostics Ltd.
Covid19
Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)
This is a double-blind study designed to investigate the efficacy, safety and PK of a single dose of COVI-DROPS or matched placebo in outpatient adults who have tested positive for COVID-19 and are either asymptomatic or have…
- Trial name
- NCT04900428
- Testing
- COVI-DROPS
- Where
- United Kingdom
- Volunteers
- 179 people
- Sponsor
- Sorrento Therapeutics, Inc.
COVID-19, Coronavirus
Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
This is a phase 2, single or multi-center, randomized, double-blind placebo-controlled study to evaluate the safety and efficacy of Rayaldee (CTAP101 Capsules) to treat adult subjects with mild to moderate COVID-19 who test…
- Conditions
- COVID-19, Coronavirus, SARS-CoV2 Infection
- Trial name
- NCT04551911
- Testing
- Rayaldee
- Where
- 10 sites in United States
- Volunteers
- 171 people
- Sponsor
- OPKO Health, Inc.
Poliomyelitis
Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia
The purpose of this study is to assess reactogenicity and safety of simultaneous administration of GSK Biologicals' inactivated poliomyelitis vaccine Poliorix and GSK Biologicals' DTPa-vaccine Infanrix vaccines in healthy…
- Trial name
- NCT01094171
- Testing
- Poliorix TM, Infanrix TM
- Where
- 2 sites in Russia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C, Hepatocellular Carcinoma
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
The primary objective is to determine if the administration of a combination of sofosbuvir (SOF; GS-7977; PSI-7977) and ribavirin (RBV) to HCV-infected adults with hepatocellular carcinoma (HCC) meeting the MILAN criteria prior…
- Trial name
- NCT01559844
- Testing
- Sofosbuvir, Ribavirin
- Where
- 15 sites in United States, New Zealand and 1 more
- Volunteers
- 61 people
- Sponsor
- Gilead Sciences
COVID-19, SARS-CoV-2
Study to Assess Safety, Reactogenicity and Immunogenicity of the repRNA(QTP104) Vaccine Against SARS-CoV-2(COVID-19)
This study is to evaluate the safety, reactogenicity, and immunogenicity of the QTP104 vaccine against SARS-CoV-2 infection in healthy adults.
- Trial name
- NCT05876364
- Testing
- QTP104 1ug, QTP104 5ug, QTP104 25ug
- Where
- 2 sites in South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Quratis Inc.
COVID-19
A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients
The purpose of this study is to assess the safety and efficacy of Alvesco (ciclesonide) Inhalation Aerosol in non hospitalized patients with symptomatic COVID-19 infection in a multicenter, randomized, double-blind, placebo…
- Trial name
- NCT04377711
- Testing
- Ciclesonide
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Covis Pharma S.à.r.l.
Covid19
The Prevent Severe COVID-19 (PRESECO) Study
Double-blinded, placebo control, randomized, phase-3 clinical trial to evaluate clinical efficacy of Favipiravir in patients with mild to moderate symptoms related to COVID-19 infection
- Trial name
- PRESECO (NCT04600895)
- Testing
- Favipiravir
- Where
- 38 sites in United States, Brazil and 1 more
- Volunteers
- 1,187 people
- Sponsor
- Appili Therapeutics Inc.
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.